Overview: 2-Hydroxyglutaric Acid TestIntroduction: The 2-Hydroxyglutaric Acid Test tests for high levels of a substance that may indicate 2-Hydroxyglutaric Aciduria, a rare disorder causing developmental delays, seizures, or brain problems, especially in children. With an incidence of less than 1 in 100,000, this metabolic condition results from mutations in genes like L2HGDH or D2HGDH, presenting unique diagnostic challenges due to its rarity and variable symptoms, including subtle early signs like hypotonia or macrocephaly. Following 2023 ACMG guidelines, it uses gas chromatography-mass spectrometry (GC-MS) for high specificity, supporting neurological symptom screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in biochemistry, particularly in pediatric neurology where early intervention with riboflavin or dietary adjustments can mitigate brain damage.
Other Names: 2-HG Assay, Hydroxyglutarate Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: 2-Hydroxyglutaric acid testing began in the 1980s with metabolic disorder research by Cornelis Jakobs, who identified the condition through urine organic acid analysis. Gas chromatography-mass spectrometry (GC-MS) methods improved in the 2000s with advancements in mass spectrometry technology by companies like Agilent, offering precise metabolite profiling for rare diseases, surpassing earlier thin-layer chromatography techniques that were less reliable for low-level detection.
Purpose: Measures 2-hydroxyglutaric acid levels to diagnose 2-Hydroxyglutaric Aciduria, guides treatment with riboflavin, ketogenic diets, or antioxidants, and evaluates patients with developmental delays, seizures, or neurological symptoms, aiming to prevent progressive neurological decline, including leukodystrophy or epilepsy that can emerge in untreated cases.
Test Parameters: 2-HG levels
Pretest Condition: No special preparation required to reflect natural metabolite levels. Collect urine, plasma, or cerebrospinal fluid (CSF). Report history of developmental delays, seizures, or neurological symptoms, including any recent infections or dietary changes.
Specimen: Urine (sterile container, 5-20 mL), Plasma (NaHep, 2-4 mL), CSF (sterile container, 1-2 mL); 10 mL urine in sterile container or 2 mL plasma in Na Heparin tube. Transport in a biohazard container to maintain sample integrity.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document developmental delays, seizures, or history of neurological issues. Include current medications, recent infections, or family history of metabolic disorders, noting any dietary restrictions that might influence metabolite levels.
Consent: Written consent required, detailing the test's purpose, 2-Hydroxyglutaric Aciduria implications (e.g., brain atrophy, intellectual disability risks), and risks of sample collection, with emphasis on genetic testing options and long-term neurological monitoring.
Procedural Considerations: Uses GC-MS to measure 2-hydroxyglutaric acid levels, requiring laboratories with Agilent 7890A GC-MS systems and trained technicians to handle volatile metabolites. Results are available in 2-3 days, supporting clinical decisions. Performed in laboratories, often for rare metabolic disorder diagnosis, with strict sample handling to preserve metabolite integrity, including immediate freezing if delays are anticipated.
Factors Affecting Result Accuracy: Improper sample collection, contamination with bacteria, or exposure to heat can affect results. Dietary factors (e.g., high protein intake), medications, or dehydration may alter levels, requiring controlled conditions and clinical correlation to avoid misdiagnosis.
Clinical Significance: Elevated 2-HG confirms 2-Hydroxyglutaric Aciduria, guiding dietary or supportive therapy with riboflavin or antioxidants. For instance, a child with early diagnosis might avoid severe epilepsy or motor deficits with timely intervention, while untreated cases may progress to gliomas or other malignancies. Normal levels may require brain MRI or genetic testing (e.g., L2HGDH sequencing) to rule out mimics like mitochondrial disorders or asymptomatic carriers.
Specialist Consultation: Consult a neurologist or metabolic geneticist for result interpretation and treatment planning, especially for infants or those with a family history, where multidisciplinary care involving dietitians and neurologists is essential.
Additional Supporting Tests: Brain MRI to assess leukodystrophy, genetic sequencing (e.g., L2HGDH, D2HGDH), or urine organic acid analysis to confirm 2-Hydroxyglutaric Aciduria diagnosis and guide therapy, addressing potential comorbidities like seizures.
Test Limitations: Non-specific for disorder subtype (D- vs. L-2-hydroxyglutaric aciduria); clinical correlation with imaging and genetics is needed. Sample quality affects sensitivity, and false negatives may occur in asymptomatic carriers, necessitating longitudinal follow-up.
References: ACMG Metabolic Guidelines, 2023; Journal of Inherited Metabolic Disease, Van Schaftingen E, 2022.
